查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1703269

非临床试验市场－全球产业规模、份额、趋势、机会和预测，按研究类型、按测试、按治疗领域、按最终用户、按地区和竞争进行细分，2020 年至 2030 年

Non-Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Study Type, By Test, By Therapeutic Area, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 187 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球非临床试验市场价值为 113.6 亿美元，预计到 2030 年将达到 169.5 亿美元，复合年增长率为 6.87%。全球非临床试验市场是製药和医疗保健产业中一个充满活力且不可或缺的组成部分，在新药和医疗器材的开发和批准中发挥关键作用。这个市场涵盖了在人类身上测试潜在治疗或疗法之前发生的广泛活动。非临床试验，通常称为临床前试验，涉及对动物、体外系统或电脑模拟进行的一系列严格测试和评估，以评估实验药物和医疗产品的安全性、有效性和毒性。全球非临床试验市场成长的主要驱动力之一是针对各种健康状况和疾病的创新药品和医疗设备的需求不断增长。因此，製药和生物技术公司以及学术研究机构在非临床试验方面投入了大量资金，以确保其产品符合监管标准并且对人类使用安全。这导致非临床试验服务外包给专门合约研究组织（CRO）的数量激增，进一步推动了市场扩张。

市场概览
预测期 2026-2030
2024年市场规模 113.6亿美元
2030年市场规模 169.5亿美元
2025-2030 年复合年增长率 6.87%
成长最快的领域 製药和生物技术公司
最大的市场 北美洲

关键市场驱动因素

对创新药品和医疗器材的需求不断增长

主要市场挑战

严格的监理合规性

主要市场趋势

创新疗法的兴起

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：全球非临床试验市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依研究类型（药效学 (PD) 研究、药物动力学 (PK) 研究、毒理学研究）
    • 通过测试（电脑模拟、体外、体内）
    • 依治疗领域（肿瘤学、心血管病学、神经病学、免疫学、其他）
    • 按最终用户（製药和生物技术公司、合约研究组织 (CRO)、学术和政府研究机构、其他）
    • 按地区
    • 按公司分类（2024）
  • 市场地图
    • 按学习类型
    • 通过测试
    • 按治疗领域
    • 按最终用户
    • 按地区

第五章：亚太非临床试验市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 按学习类型
    • 通过测试
    • 按治疗领域
    • 按最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 澳洲
    • 日本
    • 韩国

第六章：欧洲非临床试验市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第七章：北美非临床试验市场展望

  • 市场规模和预测
  • 市场占有率和预测
    • 学习类型
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第八章：南美洲非临床试验市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第九章：中东和非洲非临床试验市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第十章：市场动态

  • 驱动程式
  • 挑战

第 11 章：市场趋势与发展

  • 最新动态
  • 产品发布
  • 併购

第 12 章：全球非临床试验市场：SWOT 分析

第 13 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 14 章：竞争格局

  • Labcorp Drug Development
  • Charles River Laboratories
  • PPD (Pharmaceutical Product Development)
  • ICON plc
  • Novartis AG
  • Merck & Co., Inc.
  • AstraZeneca plc
  • CMIC HOLDINGS Co., LTD
  • ProPharma
  • MorphoSys AG

第 15 章：策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 16882

Global Non-Clinical Trials Market was valued at USD 11.36 Billion in 2024 and is expected to reach USD 16.95 Billion in the forecast period with a CAGR of 6.87% through 2030. The Global Non-Clinical Trials Market represents a dynamic and essential component of the pharmaceutical and healthcare industries, playing a pivotal role in the development and approval of new drugs and medical devices. This market encompasses a wide range of activities that occur before a potential treatment or therapy is tested on human subjects. Non-clinical trials, often referred to as preclinical trials, involve a series of rigorous tests and evaluations conducted on animals, in vitro systems, or computer simulations to assess the safety, efficacy, and toxicity of experimental drugs and medical products. One of the key drivers behind the growth of the global non-clinical trials market is the ever-increasing demand for innovative pharmaceuticals and medical devices to address a myriad of health conditions and diseases. As a result, pharmaceutical and biotechnology companies, as well as academic research institutions, are heavily invested in non-clinical trials to ensure that their products meet regulatory standards and are safe for human use. This has led to a surge in the outsourcing of non-clinical trial services to specialized contract research organizations (CROs), further fueling market expansion.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 11.36 Billion
Market Size 2030USD 16.95 Billion
CAGR 2025-20306.87%
Fastest Growing SegmentPharmaceutical and Biotechnology Companies
Largest MarketNorth America

Key Market Drivers

Rising Demand for Innovative Pharmaceuticals and Medical Devices

The global demand for innovative pharmaceuticals and medical devices is a primary driver behind the robust growth of the Global Non-Clinical Trials Market. As the global population ages and the prevalence of chronic diseases continues to escalate, there is an increasing need for cutting-edge therapies and medical solutions. This burgeoning demand has propelled pharmaceutical and biotechnology companies, as well as academic research institutions, into an intense race to develop new drugs and devices that address a wide spectrum of health conditions.

Non-clinical trials, also known as preclinical trials, are instrumental in meeting this demand by providing a crucial testing ground for these innovative products before they advance to human clinical trials. These trials involve comprehensive assessments of safety, efficacy, and toxicity, which are essential for regulatory approval and eventual market access. In 2023, research and development spending in the pharmaceutical industry exceeded USD 300 billion globally, highlighting the industry's commitment to innovation and the critical role of non-clinical trials in the drug development process.

Key Market Challenges

Stringent Regulatory Compliance

Complex and Evolving Regulations: Regulatory agencies, such as the FDA in the United States and the EMA in Europe, have developed comprehensive guidelines that govern non-clinical trials. However, these regulations are intricate, subject to frequent updates, and can vary from one region to another. Navigating this complex regulatory landscape demands substantial expertise and resources, which can slow down the initiation and progression of non-clinical trials. Stringent Data and Documentation Requirements: Regulatory authorities require extensive documentation and data to support non-clinical trial submissions. Researchers must meticulously document every aspect of the trial, from study design and procedures to results and statistical analyses. This demanding documentation process can be time-consuming and resource-intensive, diverting valuable time and resources away from research activities.

Ethical and Patient Safety Considerations: Regulatory compliance often entails rigorous ethical considerations and a focus on patient safety. These ethical standards necessitate adherence to guidelines that protect the welfare of research subjects, whether they are animals or humans. Ensuring compliance with these ethical standards can lead to additional hurdles and delays, particularly when addressing the safety and well-being of trial participants. Meeting regulatory compliance requirements is resource-intensive. Companies and research organizations must invest in state-of-the-art facilities, skilled personnel, and advanced technologies to conduct non-clinical trials that satisfy regulatory standards.

Key Market Trends

Rise in Innovative Therapies

The Global Non-Clinical Trials Market is experiencing a substantial boost due to the relentless rise in demand for innovative therapies. As the global population grapples with an increasing burden of diseases, there has been an unmistakable call for transformative pharmaceuticals and medical devices to address these health challenges. This insatiable demand for groundbreaking treatments has spurred pharmaceutical and biotechnology companies, as well as academic research institutions, to intensify their research and development efforts. Consequently, non-clinical trials have taken center stage as a pivotal phase in the development of these innovative therapies.

In the current landscape, innovative therapies encompass a wide spectrum of cutting-edge approaches, including precision medicine, gene therapies, immunotherapies, and targeted therapeutics, among others. These novel treatments hold the promise of offering highly effective and personalized solutions for a range of health conditions, from rare genetic disorders to complex cancers. However, before these therapies can advance to human clinical trials and eventually reach patients, they must undergo rigorous assessment in non-clinical trials.

Key Market Players

  • Labcorp Drug Development
  • Charles River Laboratories
  • PPD (Pharmaceutical Product Development)
  • ICON plc
  • Novartis AG
  • Merck & Co., Inc.
  • AstraZeneca plc
  • Cmic Holdings Co., Ltd
  • ProPharma
  • MorphoSys AG

Report Scope:

In this report, the Global Non-Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Clinical Trials Market, By Study Type:

  • Pharmacodynamics (PD) studies
  • Pharmacokinetics (PK) studies
  • Toxicology studies

Non-Clinical Trials Market, By Test:

  • In silico
  • In vitro
  • In vivo

Non-Clinical Trials Market, By Therapeutic Area:

  • Oncology
  • Cardiovascular
  • Neurology
  • Immunology
  • Others

Non-Clinical Trials Market, By End User:

  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Academic and Government Research Institutes
  • Others

Non-Clinical Trials Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Clinical Trials Market.

Available Customizations:

Global Non-Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Non-Clinical Trials Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Study Type (Pharmacodynamics (PD) studies, Pharmacokinetics (PK) studies, Toxicology studies)
    • 4.2.2. By Test (In silico, In vitro, In vivo )
    • 4.2.3. By Therapeutic Area (Oncology, Cardiovascular, Neurology, Immunology, Others)
    • 4.2.4. By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Academic and Government Research Institutes, Others )
    • 4.2.5. By Region
    • 4.2.6. By Company (2024)
  • 4.3. Market Map
    • 4.3.1. By Study Type
    • 4.3.2. By Test
    • 4.3.3. By Therapeutic Area
    • 4.3.4. By End User
    • 4.3.5. By Region

5. Asia Pacific Non-Clinical Trials Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Study Type
    • 5.2.2. By Test
    • 5.2.3. By Therapeutic Area
    • 5.2.4. By End User
    • 5.2.5. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Non-Clinical Trials Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Study Type
        • 5.3.1.2.2. By Test
        • 5.3.1.2.3. By Therapeutic Area
        • 5.3.1.2.4. By End User
    • 5.3.2. India Non-Clinical Trials Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Study Type
        • 5.3.2.2.2. By Test
        • 5.3.2.2.3. By Therapeutic Area
        • 5.3.2.2.4. By End User
    • 5.3.3. Australia Non-Clinical Trials Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Study Type
        • 5.3.3.2.2. By Test
        • 5.3.3.2.3. By Therapeutic Area
        • 5.3.3.2.4. By End User
    • 5.3.4. Japan Non-Clinical Trials Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Study Type
        • 5.3.4.2.2. By Test
        • 5.3.4.2.3. By Therapeutic Area
        • 5.3.4.2.4. By End User
    • 5.3.5. South Korea Non-Clinical Trials Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Study Type
        • 5.3.5.2.2. By Test
        • 5.3.5.2.3. By Therapeutic Area
        • 5.3.5.2.4. By End User

6. Europe Non-Clinical Trials Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Study Type
    • 6.2.2. By Test
    • 6.2.3. By Therapeutic Area
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Non-Clinical Trials Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Study Type
        • 6.3.1.2.2. By Test
        • 6.3.1.2.3. By Therapeutic Area
        • 6.3.1.2.4. By End User
    • 6.3.2. Germany Non-Clinical Trials Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Study Type
        • 6.3.2.2.2. By Test
        • 6.3.2.2.3. By Therapeutic Area
        • 6.3.2.2.4. By End User
    • 6.3.3. Spain Non-Clinical Trials Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Study Type
        • 6.3.3.2.2. By Test
        • 6.3.3.2.3. By Therapeutic Area
        • 6.3.3.2.4. By End User
    • 6.3.4. Italy Non-Clinical Trials Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Study Type
        • 6.3.4.2.2. By Test
        • 6.3.4.2.3. By Therapeutic Area
        • 6.3.4.2.4. By End User
    • 6.3.5. United Kingdom Non-Clinical Trials Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Study Type
        • 6.3.5.2.2. By Test
        • 6.3.5.2.3. By Therapeutic Area
        • 6.3.5.2.4. By End User

7. North America Non-Clinical Trials Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test
    • 7.2.2. Study Type
    • 7.2.3. By End User
    • 7.2.4. By Therapeutic Area
    • 7.2.5. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Non-Clinical Trials Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Study Type
        • 7.3.1.2.2. By Test
        • 7.3.1.2.3. By Therapeutic Area
        • 7.3.1.2.4. By End User
    • 7.3.2. Mexico Non-Clinical Trials Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Study Type
        • 7.3.2.2.2. By Test
        • 7.3.2.2.3. By Therapeutic Area
        • 7.3.2.2.4. By End User
    • 7.3.3. Canada Non-Clinical Trials Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Study Type
        • 7.3.3.2.2. By Test
        • 7.3.3.2.3. By Therapeutic Area
        • 7.3.3.2.4. By End User

8. South America Non-Clinical Trials Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Study Type
    • 8.2.2. By Test
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Non-Clinical Trials Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Study Type
        • 8.3.1.2.2. By Test
        • 8.3.1.2.3. By Therapeutic Area
        • 8.3.1.2.4. By End User
    • 8.3.2. Argentina Non-Clinical Trials Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Study Type
        • 8.3.2.2.2. By Test
        • 8.3.2.2.3. By Therapeutic Area
        • 8.3.2.2.4. By End User
    • 8.3.3. Colombia Non-Clinical Trials Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Study Type
        • 8.3.3.2.2. By Test
        • 8.3.3.2.3. By Therapeutic Area
        • 8.3.3.2.4. By End User

9. Middle East and Africa Non-Clinical Trials Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Study Type
    • 9.2.2. By Drug Type
    • 9.2.3. By Therapeutic Area
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Non-Clinical Trials Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Study Type
        • 9.3.1.2.2. By Test
        • 9.3.1.2.3. By Therapeutic Area
        • 9.3.1.2.4. By End User
    • 9.3.2. Saudi Arabia Non-Clinical Trials Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Study Type
        • 9.3.2.2.2. By Drug Type
        • 9.3.2.2.3. By Therapeutic Area
        • 9.3.2.2.4. By End User
    • 9.3.3. UAE Non-Clinical Trials Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Study Type
        • 9.3.3.2.2. By Test
        • 9.3.3.2.3. By Therapeutic Area
        • 9.3.3.2.4. By End User

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Non-Clinical Trials Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Labcorp Drug Development
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Charles River Laboratories
  • 14.3. PPD (Pharmaceutical Product Development)
  • 14.4. ICON plc
  • 14.5. Novartis AG
  • 14.6. Merck & Co., Inc.
  • 14.7. AstraZeneca plc
  • 14.8. CMIC HOLDINGS Co., LTD
  • 14.9. ProPharma
  • 14.10.MorphoSys AG

15. Strategic Recommendations

16. About Us & Disclaimer